Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

ASX Announcements

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Jun 8, 2023
Launch of LUMOS2 Study
Jun 7, 2023
Constitution
Jun 5, 2023
Appointment of Non-executive Director
May 26, 2023
Kazia CEO participates in White House Cancer Moonshot Forum
May 25, 2023
Cancel - Notification of cessation of securities - KZA
May 8, 2023
Notification regarding unquoted securities - KZA
May 5, 2023
Notification of cessation of securities - KZA
May 2, 2023
Final Director's Interest Notice - Dr J Garner
May 1, 2023
Executive Leadership changes - Dr John Friend appointed CEO
Apr 28, 2023
Quarterly Activities/Appendix 4C Cash Flow Report
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 19
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement